About Intrepid Therapeutics
Intrepid Therapeutics, Inc. is an independent, privately owned specialty pharmaceutical company based in San Diego, California, involved in licensing and developing innovative prescription drugs for dermatological conditions. Intrepid is currently developing a new molecular entity, CB-03-01 (cortexolone 17α-propionate), with Cosmo Pharmaceuticals. CB-03-01 is a peripherally selective, topical antiandrogen steroidal ester under development for the treatment of both acne vulgaris and androgenic alopecia. Acne vulgaris affects 40-50 million people in the United States. Androgenic alopecia affects over 80 million people in the United States.